Pulmatrix Q3 2024 revenue down 79% YoY to $0.4M; cash runway into Q4 2026

Pulmatrix, Inc.

2024-Q3 EPS reported -$2.07 revenue$7,803,000

Net loss $2.6M ($0.71 per share) vs $3.8M ($1.03) in Q3 2023.
Revenue fell to $0.4M from $1.8M due to PUR1900 wind down; R&D expenses cut 80% to $0.8M.
Cash and equivalents $10.8M; company expects funding into Q4 2026.
Completed wind down of PUR1900 Phase 2b; no further financial obligation, to receive 2% royalties ex-US.
Closed MannKind cross-license for iSPERSE technology; pursuing strategic alternatives.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.